---
document_datetime: 2025-11-23 08:05:25
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ibandronic-acid-sandoz.html
document_name: ibandronic-acid-sandoz.html
version: success
processing_time: 0.104215
conversion_datetime: 2025-12-23 21:22:18.793409
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ibandronic Acid Sandoz

[RSS](/en/individual-human-medicine.xml/66648)

##### Authorised

This medicine is authorised for use in the European Union

ibandronic acid

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Ibandronic Acid Sandoz](#more-information-on-ibandronic-acid-sandoz-1382)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Ibandronic Acid Sandoz. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ibandronic Acid Sandoz.

Expand section

Collapse section

## What is Ibandronic Acid Sandoz?

Ibandronic Acid Sandoz is a medicine that contains the active substance ibandronic acid. It is available as tablets (50 mg).

Ibandronic Acid Sandoz is a 'generic medicine'. This means that Ibandronic Acid Sandoz is similar to a 'reference medicine' already authorised in the European Union (EU). The reference medicine for Ibandronic Acid Sandoz is Bondronat.

## What is Ibandronic Acid Sandoz used for?

Ibandronic Acid Sandoz is used to prevent 'skeletal events' (fractures [broken bones] or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone).

The medicine can only be obtained with a prescription.

## How is Ibandronic Acid Sandoz used?

The recommended dose is one tablet taken once a day. The tablets must always be taken after the patient has fasted overnight for at least six hours and at least 30 minutes before the first food or drink of the day.

Ibandronic Acid Sandoz must be taken with a full glass of plain water (but not mineral water) while standing or sitting up, and the tablets should not be chewed, sucked or crushed. The patient must also not lie down for one hour after taking the tablets.

## How does Ibandronic Acid Sandoz work?

The active substance in Ibandronic Acid Sandoz, ibandronic acid, is a bisphosphonate. It stops the action of osteoclasts, the cells in the body that are involved in breaking down the bone tissue. This leads to less bone loss. The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.

## How has Ibandronic Acid Sandoz been studied?

Because Ibandronic Acid Sandoz is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine. Medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Ibandronic Acid Sandoz?

Because Ibandronic Acid Sandoz is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why has Ibandronic Acid Sandoz been approved?

The CHMP concluded that, in accordance with EU requirements, Ibandronic Acid Sandoz has been shown to have comparable quality and to be bioequivalent to Bondronat. Therefore, the CHMP's view was that, as for Bondronat, the benefit outweighs the identified risk. The Committee recommended that Ibandronic Acid Sandoz be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Ibandronic Acid Sandoz?

A risk management plan has been developed to ensure that Ibandronic Acid Sandoz is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ibandronic Acid Sandoz, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Ibandronic Acid Sandoz:

The European Commission granted a marketing authorisation valid throughout the EU for Ibandronic Acid Sandoz on 26 July 2011.

For more information about treatment with Ibandronic Acid Sandoz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Ibandronic Acid Sandoz : EPAR - Summary for the public

English (EN) (79.65 KB - PDF)

**First published:** 04/08/2011

**Last updated:** 19/06/2015

[View](/en/documents/overview/ibandronic-acid-sandoz-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-913)

български (BG) (107.72 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/bg/documents/overview/ibandronic-acid-sandoz-epar-summary-public_bg.pdf)

español (ES) (78.69 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/es/documents/overview/ibandronic-acid-sandoz-epar-summary-public_es.pdf)

čeština (CS) (125.17 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/cs/documents/overview/ibandronic-acid-sandoz-epar-summary-public_cs.pdf)

dansk (DA) (101.24 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/da/documents/overview/ibandronic-acid-sandoz-epar-summary-public_da.pdf)

Deutsch (DE) (103.23 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/de/documents/overview/ibandronic-acid-sandoz-epar-summary-public_de.pdf)

eesti keel (ET) (100.85 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/et/documents/overview/ibandronic-acid-sandoz-epar-summary-public_et.pdf)

ελληνικά (EL) (106.25 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/el/documents/overview/ibandronic-acid-sandoz-epar-summary-public_el.pdf)

français (FR) (101.62 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/fr/documents/overview/ibandronic-acid-sandoz-epar-summary-public_fr.pdf)

hrvatski (HR) (98.58 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/hr/documents/overview/ibandronic-acid-sandoz-epar-summary-public_hr.pdf)

italiano (IT) (78.79 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/it/documents/overview/ibandronic-acid-sandoz-epar-summary-public_it.pdf)

latviešu valoda (LV) (122.68 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/lv/documents/overview/ibandronic-acid-sandoz-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (101.29 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/lt/documents/overview/ibandronic-acid-sandoz-epar-summary-public_lt.pdf)

magyar (HU) (121.2 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/hu/documents/overview/ibandronic-acid-sandoz-epar-summary-public_hu.pdf)

Malti (MT) (126.79 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/mt/documents/overview/ibandronic-acid-sandoz-epar-summary-public_mt.pdf)

Nederlands (NL) (80.44 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/nl/documents/overview/ibandronic-acid-sandoz-epar-summary-public_nl.pdf)

polski (PL) (126.92 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/pl/documents/overview/ibandronic-acid-sandoz-epar-summary-public_pl.pdf)

português (PT) (101.05 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/pt/documents/overview/ibandronic-acid-sandoz-epar-summary-public_pt.pdf)

română (RO) (98.41 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/ro/documents/overview/ibandronic-acid-sandoz-epar-summary-public_ro.pdf)

slovenčina (SK) (101.9 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/sk/documents/overview/ibandronic-acid-sandoz-epar-summary-public_sk.pdf)

slovenščina (SL) (96.64 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/sl/documents/overview/ibandronic-acid-sandoz-epar-summary-public_sl.pdf)

Suomi (FI) (79.28 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/fi/documents/overview/ibandronic-acid-sandoz-epar-summary-public_fi.pdf)

svenska (SV) (78.92 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

19/06/2015

[View](/sv/documents/overview/ibandronic-acid-sandoz-epar-summary-public_sv.pdf)

## Product information

Ibandronic acid Sandoz : EPAR - Product Information

English (EN) (192.88 KB - PDF)

**First published:** 04/08/2011

**Last updated:** 06/07/2022

[View](/en/documents/product-information/ibandronic-acid-sandoz-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-347)

български (BG) (246.53 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/bg/documents/product-information/ibandronic-acid-sandoz-epar-product-information_bg.pdf)

español (ES) (195.73 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/es/documents/product-information/ibandronic-acid-sandoz-epar-product-information_es.pdf)

čeština (CS) (216.13 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/cs/documents/product-information/ibandronic-acid-sandoz-epar-product-information_cs.pdf)

dansk (DA) (190.77 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/da/documents/product-information/ibandronic-acid-sandoz-epar-product-information_da.pdf)

Deutsch (DE) (202.58 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/de/documents/product-information/ibandronic-acid-sandoz-epar-product-information_de.pdf)

eesti keel (ET) (183.72 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/et/documents/product-information/ibandronic-acid-sandoz-epar-product-information_et.pdf)

ελληνικά (EL) (230.97 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/el/documents/product-information/ibandronic-acid-sandoz-epar-product-information_el.pdf)

français (FR) (201.39 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/fr/documents/product-information/ibandronic-acid-sandoz-epar-product-information_fr.pdf)

hrvatski (HR) (200.45 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/hr/documents/product-information/ibandronic-acid-sandoz-epar-product-information_hr.pdf)

íslenska (IS) (194.81 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/is/documents/product-information/ibandronic-acid-sandoz-epar-product-information_is.pdf)

italiano (IT) (209.83 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/it/documents/product-information/ibandronic-acid-sandoz-epar-product-information_it.pdf)

latviešu valoda (LV) (206.94 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/lv/documents/product-information/ibandronic-acid-sandoz-epar-product-information_lv.pdf)

lietuvių kalba (LT) (211.61 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/lt/documents/product-information/ibandronic-acid-sandoz-epar-product-information_lt.pdf)

magyar (HU) (210.33 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/hu/documents/product-information/ibandronic-acid-sandoz-epar-product-information_hu.pdf)

Malti (MT) (242.85 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/mt/documents/product-information/ibandronic-acid-sandoz-epar-product-information_mt.pdf)

Nederlands (NL) (199.47 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/nl/documents/product-information/ibandronic-acid-sandoz-epar-product-information_nl.pdf)

norsk (NO) (191.18 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/no/documents/product-information/ibandronic-acid-sandoz-epar-product-information_no.pdf)

polski (PL) (219.5 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/pl/documents/product-information/ibandronic-acid-sandoz-epar-product-information_pl.pdf)

português (PT) (199.92 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/pt/documents/product-information/ibandronic-acid-sandoz-epar-product-information_pt.pdf)

română (RO) (230.13 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/ro/documents/product-information/ibandronic-acid-sandoz-epar-product-information_ro.pdf)

slovenčina (SK) (222.16 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/sk/documents/product-information/ibandronic-acid-sandoz-epar-product-information_sk.pdf)

slovenščina (SL) (201.67 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/sl/documents/product-information/ibandronic-acid-sandoz-epar-product-information_sl.pdf)

Suomi (FI) (190.31 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/fi/documents/product-information/ibandronic-acid-sandoz-epar-product-information_fi.pdf)

svenska (SV) (179.3 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

06/07/2022

[View](/sv/documents/product-information/ibandronic-acid-sandoz-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0021 06/07/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ibandronic acid Sandoz : EPAR - All Authorised presentations

English (EN) (26.82 KB - PDF)

**First published:** 04/08/2011

**Last updated:** 04/08/2011

[View](/en/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-50)

български (BG) (95.25 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/bg/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_bg.pdf)

español (ES) (27.53 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/es/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_es.pdf)

čeština (CS) (93.3 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/cs/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (23.73 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/da/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (26.86 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/de/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (27.06 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/et/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (94.83 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/el/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_el.pdf)

français (FR) (27.89 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/fr/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (27.78 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/is/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_is.pdf)

italiano (IT) (27.37 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/it/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (92.75 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/lv/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (91.62 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/lt/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (93.55 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/hu/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (92.24 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/mt/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (26.83 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/nl/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (27.15 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/no/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_no.pdf)

polski (PL) (57.26 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/pl/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_pl.pdf)

português (PT) (27.21 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/pt/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_pt.pdf)

română (RO) (91.03 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/ro/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (57.45 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/sk/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (27.04 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/sl/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (27.28 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/fi/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (27.72 KB - PDF)

**First published:**

04/08/2011

**Last updated:**

04/08/2011

[View](/sv/documents/all-authorised-presentations/ibandronic-acid-sandoz-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ibandronic Acid Sandoz Active substance ibandronic acid International non-proprietary name (INN) or common name ibandronic acid Therapeutic area (MeSH)

- Breast Neoplasms
- Neoplasm Metastasis
- Fractures, Bone

Anatomical therapeutic chemical (ATC) code M05BA06

### Pharmacotherapeutic group

- Drugs for treatment of bone diseases
- Bisphosphonates

### Therapeutic indication

Ibandronic acid Sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

## Authorisation details

EMA product number EMEA/H/C/002367

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Sandoz GmbH

Biochemiestrasse 10

Opinion adopted 17/02/2011 Marketing authorisation issued 26/07/2011 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ibandronic acid Sandoz : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (160.5 KB - PDF)

**First published:** 11/07/2014

**Last updated:** 06/07/2022

[View](/en/documents/procedural-steps-after/ibandronic-acid-sandoz-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Ibandronic acid Sandoz : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/94879/2011

English (EN) (241.06 KB - PDF)

**First published:** 04/08/2011

**Last updated:** 04/08/2011

[View](/en/documents/assessment-report/ibandronic-acid-sandoz-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ibandronic Acid Sandoz

Adopted

Reference Number: EMA/112994/2011

English (EN) (118.1 KB - PDF)

**First published:** 18/02/2011

**Last updated:** 18/02/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ibandronic-acid-sandoz_en.pdf)

#### More information on Ibandronic Acid Sandoz

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-44)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 06/07/2022

## Share this page

[Back to top](#main-content)